Notices

- Career Award (K) Policy Update: Concurrent Support from a Mentored K Award and a Research Grant
  (NOT-OD-18-157) Office of the Director, NIH

- Change to Activity Codes for PA-18-713: Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional)
  (NOT-OD-18-163) Office of the Director, NIH

- Notice of Correction to PAR-18-598 "High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)"
  (NOT-OD-18-164) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- Notice of Correction to PAR-18-599 "Shared Instrumentation for Animal Research (SIFAR) Grant Program (S10 Clinical Trial Not Allowed)"
  (NOT-OD-18-165) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- Notice of Correction to PAR-18-600 "Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)"
  (NOT-OD-18-166) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

  (NOT-CA-18-056) National Cancer Institute

- NCI Request for Information (RFI): Input on Development of the NCI Imaging Data Commons
  (NOT-CA-18-060) National Cancer Institute

- Notice of NCI’s participation on PAR-18-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
  (NOT-CA-18-061) National Cancer Institute National Institute on Drug Abuse
• Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue of PA-18-568
  International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)
  (NOT-DA-18-010)
  National Institute on Drug Abuse

• NIDCR Policy on Applications for Investigator-Initiated Clinical Trials
  (NOT-DE-18-014)
  National Institute of Dental and Craniofacial Research

• Notice of Corrected Application Forms for PAR-18-547, NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (NOT-DE-18-016)
  National Institute of Dental and Craniofacial Research

• Request for Information (RFI): NHLBI R35 Programs
  (NOT-HL-18-614)
  National Heart, Lung, and Blood Institute

• Notice of NINDS Policy for Submission of Applications Containing Clinical Trials
  (NOT-NS-18-054)
  National Institute of Neurological Disorders and Stroke

Requests for Applications

• Impact of Initial Influenza Exposure onImmunity in Infants (U01 Clinical Trial Not Allowed)
  (RFA-AI-18-010)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
  (RFA-AR-19-006)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): August 7, 2018; December 4, 2018; April 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
  (RFA-AR-19-007)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): August 7, 2018; December 4, 2018; April 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow
adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications to National Cancer Institute (NCI) Supported R01 Awards to Include Research on the NCIs Provocative Questions (R01 Clinical Trial Optional)** *(RFA-CA-18-021)*
  National Cancer Institute
  Application Receipt Date(s): June 29, 2018, October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications to National Cancer Institute (NCI) supported U01 Awards to Include Research on the NCIs Provocative Questions (U01 Clinical Trial Optional)** *(RFA-CA-18-022)*
  National Cancer Institute
  Application Receipt Date(s): June 29, 2018, October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCIs Provocative Questions (P01 Clinical Trial Optional)** *(RFA-CA-18-023)*
  National Cancer Institute
  Application Receipt Date(s): June 29, 2018; October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCIs Provocative Questions (P50 Clinical Trial Optional)** *(RFA-CA-18-024)*
  National Cancer Institute
  Application Receipt Date(s): June 29, 2018; October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity.

- **Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)** *(RFA-DK-18-005)*
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): December 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity.
Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed)**
  (RFA-RM-18-006)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): June 11, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)**
  (RFA-RM-18-011)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 9, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Funding Opportunity Announcement.

### Program Announcements

- **Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional).**
  (PA-18-738)
  National Cancer Institute
  National Institute on Aging
  National Institute of Dental and Craniofacial Research
  National Institute of Nursing Research
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional).**
  (PA-18-739)
  National Cancer Institute
  National Institute on Aging
  National Institute of Dental and Craniofacial Research
  National Institute of Nursing Research
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
(NA-18-741)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional)
(PAR-18-735)
National Human Genome Research Institute
Application Receipt/Submission Date(s): June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional)
(PAR-18-736)
National Human Genome Research Institute
Application Receipt/Submission Date(s): June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)
(PAR-18-737)
National Institute of Mental Health
Application Receipt/Submission Date(s): June 22, 2018; May 24, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional) (PAR-18-740)
  National Institutes of Health
  National Cancer Institute
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Application Receipt/Submission Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional) (PAR-18-742)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  Application Receipt/Submission Date(s): July 17, 2018, November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional) (PAR-18-743)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional) (PAR-18-744)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt/Submission Date(s): Standard dates apply), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow
adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) (PAR-18-746)
  National Institute on Drug Abuse
  Application Receipt/Submission Date(s): June 11, 2018; June 11, 2019; June 11, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.